TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth.

TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth.

Despite its initial positive response to hormone ablation therapy, prostate cancers invariably recur in more aggressive, treatment resistant forms. The lack of our understanding of underlying genetic alterations for the transition from androgen-dependent (AD) to ADI prostate cancer growth hampers ou...

Full description

Bibliographic Details
Main Authors: Joseph H Jeong, Ayesha Bhatia, Zsolt Toth, Soohwan Oh, Kyung-Soo Inn, Chun-Peng Liao, Pradip Roy-Burman, Jonathan Melamed, Gerhard A Coetzee, Jae U Jung
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3022761?pdf=render

Internet

http://europepmc.org/articles/PMC3022761?pdf=render

Similar Items